Skip to main content
Journal cover image

Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma.

Publication ,  Journal Article
Reardon, DA; Desjardins, A; Vredenburgh, JJ; Herndon, JE; Coan, A; Gururangan, S; Peters, KB; McLendon, R; Sathornsumetee, S; Rich, JN ...
Published in: Cancer
October 1, 2012

BACKGROUND: We evaluated the efficacy of imatinib plus hydroxyurea in patients with progressive/recurrent low-grade glioma. METHODS: A total of 64 patients with recurrent/progressive low-grade glioma were enrolled in this single-center study that stratified patients into astrocytoma and oligodendroglioma cohorts. All patients received 500 mg of hydroxyurea twice a day. Imatinib was administered at 400 mg per day for patients not on enzyme-inducing antiepileptic drugs (EIAEDs) and at 500 mg twice a day if on EIAEDs. The primary endpoint was progression-free survival at 12 months (PFS-12) and secondary endpoints were safety, median progression-free survival, and radiographic response rate. RESULTS: Thirty-two patients were enrolled into each cohort. Eleven patients (17%) had before radiotherapy and 24 (38%) had received before chemotherapy. The median PFS and PFS-12 were 11 months and 39%, respectively. Outcome did not differ between the histologic cohorts. No patient achieved a radiographic response. The most common grade 3 or greater adverse events were neutropenia (11%), thrombocytopenia (3%), and diarrhea (3%). CONCLUSIONS: Imatinib plus hydroxyurea was well tolerated among recurrent/progressive LGG patients but this regimen demonstrated negligible antitumor activity.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Cancer

DOI

EISSN

1097-0142

Publication Date

October 1, 2012

Volume

118

Issue

19

Start / End Page

4759 / 4767

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Thrombocytopenia
  • Temozolomide
  • Pyrimidines
  • Piperazines
  • Oncology & Carcinogenesis
  • Oligodendroglioma
  • Neutropenia
  • Neoplasm Recurrence, Local
  • Middle Aged
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Reardon, D. A., Desjardins, A., Vredenburgh, J. J., Herndon, J. E., Coan, A., Gururangan, S., … Friedman, H. S. (2012). Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma. Cancer, 118(19), 4759–4767. https://doi.org/10.1002/cncr.26541
Reardon, David A., Annick Desjardins, James J. Vredenburgh, James E. Herndon, April Coan, Sridharan Gururangan, Katherine B. Peters, et al. “Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma.Cancer 118, no. 19 (October 1, 2012): 4759–67. https://doi.org/10.1002/cncr.26541.
Reardon DA, Desjardins A, Vredenburgh JJ, Herndon JE, Coan A, Gururangan S, et al. Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma. Cancer. 2012 Oct 1;118(19):4759–67.
Reardon, David A., et al. “Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma.Cancer, vol. 118, no. 19, Oct. 2012, pp. 4759–67. Pubmed, doi:10.1002/cncr.26541.
Reardon DA, Desjardins A, Vredenburgh JJ, Herndon JE, Coan A, Gururangan S, Peters KB, McLendon R, Sathornsumetee S, Rich JN, Lipp ES, Janney D, Friedman HS. Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma. Cancer. 2012 Oct 1;118(19):4759–4767.
Journal cover image

Published In

Cancer

DOI

EISSN

1097-0142

Publication Date

October 1, 2012

Volume

118

Issue

19

Start / End Page

4759 / 4767

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Thrombocytopenia
  • Temozolomide
  • Pyrimidines
  • Piperazines
  • Oncology & Carcinogenesis
  • Oligodendroglioma
  • Neutropenia
  • Neoplasm Recurrence, Local
  • Middle Aged